Why the “world’s first” Covid-19 vaccine spurred global scepticism
Based on the DNA of a SARS-CoV-2 type adenovirus, the vaccine has been developed by Moscow's Gamaleya Research Institute in collaboration with the Russian defence ministry.

Based on the DNA of a SARS-CoV-2 type adenovirus, the vaccine has been developed by Moscow's Gamaleya Research Institute in collaboration with the Russian defence ministry.
RDIF has seen strong global interest in the vaccine and plans to conduct Phase 3 clinical trials in different countries, including Saudi Arabia, UAE, Brazil, India and Philippines, and start mass production in other countries in partnership with local sovereign wealth funds, including India, South Korea and Brazil, as well as, in Saudi Arabia, Turkey and Cuba, according to the statement.